

# Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/HA2C108980E7EN.html>

Date: February 2020

Pages: 96

Price: US\$ 3,500.00 (Single User License)

ID: HA2C108980E7EN

## Abstracts

Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H1 2020

### SUMMARY

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase enzyme encoded by EZH2 gene. EZH2 methylates non-histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. It regulates the circadian clock via histone methylation at the promoter of the circadian genes. It is essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer, involved in the di and trimethylation of Lys-27 of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription.

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) pipeline Target constitutes close to 20 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 1, 7 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Report covers products from therapy areas Oncology and Undisclosed which include indications Lymphoma, Diffuse Large B-Cell Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Follicular Lymphoma, Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Small-Cell

Lung Cancer, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Bladder Cancer, Breast Cancer, Central Nervous System (CNS) Tumor, Chondrosarcoma, Chordoma, Endometrial Cancer, Epithelial Tumor, Glioblastoma Multiforme (GBM), Hematological Tumor, Hepatocellular Carcinoma, Leukemia, Lung Cancer, Malignant Mesothelioma, Melanoma, Metastatic Liver Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Neuroblastoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Primary Mediastinal B-Cell Lymphoma, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Squamous Non-Small Cell Lung Cancer, Synovial Sarcoma, T-Cell Leukemia, T-Cell Lymphomas, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Triple-Negative Breast Cancer (TNBC), Unspecified, Uterine Cancer and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

The latest report Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H1 2020, outlays comprehensive information on the Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43)

The report reviews Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics and enlists all their major and minor projects

The report assesses Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Overview

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Companies Involved in Therapeutics Development

Constellation Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Domainex Ltd

Epizyme Inc

Eternity Bioscience Inc

GlaxoSmithKline Plc

Hanmi Pharmaceuticals Co Ltd

Ionis Pharmaceuticals Inc

Jiangsu Hengrui Medicine Co Ltd

Kainos Medicine Inc

OncoFusion Therapeutics Inc

Pfizer Inc

Transgene Biotek Ltd

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Drug Profiles

CPI-0209 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress  
CPI-1205 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
CPI-169 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
EBI-2554 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
GSK-343 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
HM-97594 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
IONISEZH-22.5Rx - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
JQEZ-5 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
KM-301 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
MS-1943 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
ORS-1 - Drug Profile  
Product Description

Mechanism Of Action

R&D Progress

PF-06821497 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-2554 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit EZH1 and EZH2 for Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit EZH2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit EZH2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit EZH2-EED for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tazemetostat hydrobromide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TBL-0404 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

valemetostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or

Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Dormant Products  
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or  
Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Discontinued Products  
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or  
Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Product Development  
Milestones

Featured News & Press Releases

Feb 14, 2020: Epizyme announces FDA acceptance of New Drug Application for filing with priority review for TAZVERIK (tazemetostat) for the treatment of Follicular Lymphoma

Jan 24, 2020: Epizyme's Tazverik receives accelerated approval from FDA

Dec 18, 2019: Epizyme submits new drug application to the U.S. FDA for Tazemetostat for the treatment of patients with follicular lymphoma

Dec 18, 2019: Epizyme (EPZM) trading of stock halted; Oncology drug advisory committee to review Tazemetostat

Dec 18, 2019: Epizyme announces FDA Advisory Committee votes unanimously in favor of Tazemetostat for the treatment of patients with epithelioid sarcoma

Dec 11, 2019: Daiichi Sankyo initiates Phase II study of valemestostat to treat ATL

Dec 09, 2019: Researchers create a potential therapy for deadly Breast Cancer that has few treatment options

Dec 07, 2019: Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma

Dec 02, 2019: Epizyme announces FDA Advisory Committee Meeting to review Tazemetostat for the treatment of patients with epithelioid sarcoma

Nov 06, 2019: Daiichi Sankyo showcases data presentations on valemestostat at American Society of Hematology (ASH)

Oct 30, 2019: Epizyme announces positive pre-NDA meeting for Tazemetostat for Follicular Lymphoma

Sep 24, 2019: Constellation Pharmaceuticals advances CPI-0209 into Clinical Trials, expanding its EZH2 franchise

Jul 25, 2019: Epizyme announces FDA Filing Acceptance of New Drug Application and Priority Review for Tazemetostat for the Treatment of Epithelioid Sarcoma

Jun 24, 2019: Epizyme reports positive data from trial of FL therapy tazemetostat

Jun 12, 2019: Epizyme announces conference call to discuss phase 2 Tazemetostat follicular lymphoma data

Appendix

Methodology

Coverage

Secondary Research



Primary Research  
Expert Panel Validation  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020  
Number of Products under Development by Therapy Areas, H1 2020  
Number of Products under Development by Indications, H1 2020  
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020  
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020  
Number of Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Products under Development by Companies, H1 2020 (Contd..2), H1 2020  
Products under Development by Companies, H1 2020 (Contd..3), H1 2020  
Products under Development by Companies, H1 2020 (Contd..4), H1 2020  
Number of Products under Investigation by Universities/Institutes, H1 2020  
Products under Investigation by Universities/Institutes, H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Pipeline by Constellation Pharmaceuticals Inc, H1 2020  
Pipeline by Daiichi Sankyo Co Ltd, H1 2020  
Pipeline by Domainex Ltd, H1 2020  
Pipeline by Epizyme Inc, H1 2020  
Pipeline by Eternity Bioscience Inc, H1 2020  
Pipeline by GlaxoSmithKline Plc, H1 2020  
Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2020  
Pipeline by Ionis Pharmaceuticals Inc, H1 2020  
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020  
Pipeline by Kainos Medicine Inc, H1 2020  
Pipeline by OncoFusion Therapeutics Inc, H1 2020  
Pipeline by Pfizer Inc, H1 2020  
Pipeline by Transgene Biotek Ltd, H1 2020  
Dormant Projects, H1 2020  
Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

Constellation Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Domainex Ltd

Epizyme Inc

Eternity Bioscience Inc

GlaxoSmithKline Plc

Hanmi Pharmaceuticals Co Ltd

Ionis Pharmaceuticals Inc

Jiangsu Hengrui Medicine Co Ltd

Kainos Medicine Inc

OncoFusion Therapeutics Inc

Pfizer Inc

Transgene Biotek Ltd

## I would like to order

Product name: Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/HA2C108980E7EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HA2C108980E7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970